Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes

BACKGROUND: Glucocorticoid drugs are highly effective anti-inflammatory agents, but chronic use is associated with extensive pharmacodynamic safety concerns that have a considerable negative impact on patient quality of life. PURPOSE: Vamorolone (VBP15) is a first-in-class steroidal multi-functional...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffman, Eric P., Riddle, Valerie, Siegler, Maxime A., Dickerson, Daniel, Backonja, Miroslav, Kramer, William G., Nagaraju, Kanneboyina, Gordish-Dressman, Heather, Damsker, Jesse M., McCall, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136660/
https://www.ncbi.nlm.nih.gov/pubmed/29524454
http://dx.doi.org/10.1016/j.steroids.2018.02.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136660/
https://www.ncbi.nlm.nih.gov/pubmed/29524454
http://dx.doi.org/10.1016/j.steroids.2018.02.010

Ejemplares similares